Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Graves Ophthalmopathy

• An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies
• A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease
• A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
• A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease (SatraGO-2)
• A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 75 Years of Age With Thyroid Eye Disease
• Efficacy and Safety of Tocilizumab for TAO
• A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Chronic Thyroid Eye Disease (TED)
• A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Thyroid Eye Disease
• Study of ZB001 in Chinese Patients With Thyroid Eye Disease
• Efficacy and Safety of VB421 in Subjects With Thyroid Eye Disease (TED)
• Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.
• Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
• Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
• Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
• Thyroid Associated Orbitopathy Treatment by Methotrexate Against Triamcinolone Periocular Injections
• Efficacy and Safety of SHR-1314 by Subcutaneous Injection in Active Moderate to Severe Graves' Orbitopathy Patients
• A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
• Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy
• A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED)
• Hydroxychloroquine in Graves' Orbitopathy
• Multi-model Image of Doxycycline in TAO
• Multi-model Image of Immunosuppressive Agents in TAO
• A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study
• A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease
• TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study
• Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease
• Tocilizumab in Active Moderate-severe Graves' Orbitopathy
• A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy
• A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)
• Sirolimus for Graves' Orbitopathy (GO)
• A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease
• Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO
• Tamsulosin for Thyroid Lid Retraction
• Anti-VEGF Therapy for Acute Thyroid Eye Disease
• 99Tc-MDP for Thyroid-Associated Ophthalmopathy
• ASCEND GO-2: Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )
• Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy ( GO )
• Bimatoprost as a Treatment for Graves' Orbitopathy
• Treatment of Graves´Ophthalmopathy With Simvastatin (GO-DS)
• Effects of Atorvastatin in Graves' Orbitopathy (GO)
• A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy
• Celecoxib for Thyroid Eye Disease
• The Effects of Metformin in Patients With Mild Graves' Ophthalmopathy
• The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease
• The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED)
• Rituximab (RTX) Therapy in Patients With Active TAO
• Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease
• Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy
• Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues
• Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)
• A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy
• The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.
• Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment
• Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
• Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy
• Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease
• Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
• Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections
• The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy
• Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study)
• Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy
• Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease)
• Local Triamcinolone Injection in Active Thyroid Orbitopathy
• Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction
• A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease
• The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy
• Trial of Rituximab for Graves' Ophthalmopathy
• Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies
• Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy
• Effect of Percutaneous Botulinum Toxin A Injection on Natural Course of Upper Lid Retraction in Thyroid Eye Disease
• Thyroid Treatment Trial
• Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
• Rituximab in the Treatment of Graves' Disease